Sherene Loi
Researcher Next ID · RN-004517
Researcher · Medicine
Melbourne, Australia
- Works count
- 1,200
- Citation count
- 82,487
- H-index
- 128
- i10-index
- 403
Research interests
Publications
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)32531-9
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1809615
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(15)00613-0
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
Annals of Oncology · 2014 · https://doi.org/10.1093/annonc/mdu450
Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis
JNCI Journal of the National Cancer Institute · 2006 · https://doi.org/10.1093/jnci/djj052
Current projects
No projects listed.